This Department of Defense (DoD) grant supports the rapid execution of early-phase, hypothesis-driven clinical trials or correlative studies focused on prostate cancer. The primary goal is to examine innovative, untested interventions—including drugs, devices, biologics, surgical procedures, or behavior modifications—that could significantly impact prostate cancer clinical management. Proposed projects are expected to provide scientific rationale or initial proof-of-principle, paving the way for larger clinical trials. Applicants must ensure Investigational New Drug or Investigational Device Exemption approvals are secured prior to submission, and selected clinical trials are anticipated to commence within 12 months of the award date.
Opportunity ID: 156494
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-12-PCRP-CEA |
| Funding Opportunity Title: | DoD Prostate Cancer Clinical Exploration Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 3 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 20, 2012 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Aug 23, 2012 |
| Current Closing Date for Applications: | Aug 23, 2012 |
| Archive Date: | Sep 22, 2012 |
| Estimated Total Program Funding: | $2,200,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | Supports rapid execution of hypothesis-driven, early phase clinical trials or studies correlative to existing clinical trials to examine interventions that could have a major impact on prostate cancer clinical management. It is anticipated that proposed studies will explore innovative and untested concepts to provide scientific rationale or initial proof-of-principle for larger clinical trials in prostate cancer. Interventions may include drugs, devices, biologics, surgical procedures, behavior modifications, or other. Investigational New Drug or Investigational Device Exemption approvals, if applicable, must be in place before submission of the application. Clinical trials are expected to be initiated within 12 months of the award date. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk: 301-682-5507
Email:help@cdmrp.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 156494 Full Announcement-1 -> fy12 cdmrp gai final 12mar2012.pdf
Folder 156494 Full Announcement-1 -> pcrp_fy12_cea_pa_gg.pdf
Folder 156494 Full Announcement-1 -> pcrp_fy12_cea ind-ide documentation form.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk: 301-682-5507 Email: help@cdmrp.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00108831 | Mar 20, 2012 | Aug 23, 2012 | View |
Package 1
Mandatory forms
156494 RR_SF424_1_2-1.2.pdf
156494 PerformanceSite_1_4-1.4.pdf
156494 RR_Budget-1.1.pdf
156494 RR_KeyPersonExpanded_1_2-1.2.pdf
Optional forms
156494 RR_SubawardBudget30-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
